The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Rheumatol Ther
; 10(1): 73-93, 2023 Feb.
Article
in En
| MEDLINE
| ID: mdl-36227530
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Language:
En
Journal:
Rheumatol Ther
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: